150 related articles for article (PubMed ID: 9293855)
1. Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Bendandi M; Magagnoli M; Rondelli D; de Vivo A; Benni M; Zamagni E; Cavo M; Tura S
Eur J Haematol; 1997 Aug; 59(2):82-8. PubMed ID: 9293855
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
6. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
Rao R; Shammo JM; Enschede SH; Porter C; Adler SS; Venugopal P; Gregory SA
Clin Lymphoma; 2005 Jun; 6(1):26-30. PubMed ID: 15989703
[TBL] [Abstract][Full Text] [Related]
7. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
8. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
[TBL] [Abstract][Full Text] [Related]
10. FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.
Zinzani PL; Bendandi M; Gherlinzoni F; Merla E; Gozzetti A; Tura S
Haematologica; 1996; 81(2):168-71. PubMed ID: 8641650
[TBL] [Abstract][Full Text] [Related]
11. Activity of fludarabine in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma--the Jerusalem experience.
Gillis S; Dann EJ; Cass Y; Rochlemer RR; Polliack A
Leuk Lymphoma; 1994 Sep; 15(1-2):173-5. PubMed ID: 7858497
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
Lynch JW; Hei DL; Braylan RC; Rimzsa LM; Staab EV; Bewsher CJ; Mendenhall NP; Hudson JK
Am J Clin Oncol; 2002 Aug; 25(4):391-7. PubMed ID: 12151972
[TBL] [Abstract][Full Text] [Related]
13. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders.
Lazzarino M; Orlandi E; Baldanti F; Furione M; Pagnucco G; Astori C; Arcaini L; Viglio A; Paulli M; Gerna G; Bernasconi C
Br J Haematol; 1999 Dec; 107(4):877-82. PubMed ID: 10606897
[TBL] [Abstract][Full Text] [Related]
14. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience.
O'Brien ME; Matutes E; Cunningham D; Hill M; Emmett E; Ellis PA; Milan S; Hickish T; Mercieca J; Catovsky D
Leuk Lymphoma; 1994; 14 Suppl 2():17-23. PubMed ID: 7881347
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F
Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas.
Fenchel K; Bergmann L; Wijermans P; Engert A; Pralle H; Mitrou PS; Diehl V; Hoelzer D
Leuk Lymphoma; 1995 Aug; 18(5-6):485-92. PubMed ID: 8528057
[TBL] [Abstract][Full Text] [Related]
18. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Keating MJ; O'Brien S; Lerner S; Koller C; Beran M; Robertson LE; Freireich EJ; Estey E; Kantarjian H
Blood; 1998 Aug; 92(4):1165-71. PubMed ID: 9694704
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ
Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
